Tumor-Nipple Distance of ≥ 1 cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

Tumor-Nipple Distance of ≥ 1 cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy

Published:2021-04-17 Issue:11 Volume:28 Page:6024-6029
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Moo Tracy-Ann,Saccarelli Carolina Rossi,Sutton Elizabeth J.,Sevilimedu Varadan,Pawloski Kate R.,D’Alfonso Timothy M.,Hughes Mary C.,Gluskin Jill S.,Bitencourt Almir,Morris Elizabeth A.,Tadros Audree,Morrow Monica,Gemignani Mary L.,Sacchini Virgilio

Funder

National Institute of Health

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-021-09902-2.pdf

Reference21 articles.

1. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.

2. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.

3. Singh JC, Mamtani A, Barrio A, et al. Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: a single center experience. Oncologist. 2017;22(2):139–43.